Entrepreneurial behaviour in pharmaceutical markets and the effects of regulation

Abstract

Contending that European policy makers, in their efforts to protect patient's health, have enacted an overly bureaucratic and static regulatory regime, this collection of 11 papers argues for a new regulatory regime that allows for more entrepreneurial "innovation," while still protecting the quality of service of the health care systems. Authors discuss the lessons learned from the regulation of the public utilities, accreditation as a means for the regulation of quality, the challenge of corruption, the effects of regulation on entrepreneurship in the pharmaceutical markets, and an international perspective on the regulatory environment of general practice